STERIS plc (STE) Stock Price & Analysis
STERIS plc (STE) closed at USD 232.22 on Thursday, October 22, 2026, up 4.85% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 221.48; the Oct 22, 2026 session ranged USD 222.78–232.32 on volume of 1,024,626 shares. Market capitalization is $22.64B, with a 52-week range of USD 195.14–269.44 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/STE.md
Key facts (STE)
- Last four reported quarters (through Jun 30, 2026): revenue $6.04B, net income $805M (13.3% margin), free cash flow $926M (SEC filings).
- Valuation: P/E 28.1x (avg 41.2x at the last 3 fiscal year-ends), EV/EBITDA 14.7x, net debt $1.41B.
- 1 of 80 tracked superinvestors hold STE (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (8 analysts), mean target USD 259.17 (range 232–275).
- Total return with dividends: 1Y -3.2% vs S&P 500 +14.9%; 5Y +3.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 2.68, revenue estimate $1.56B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (STE)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $4.22B | $4.54B | $5.14B | $5.46B | $5.94B | $6.04B |
| Gross profit | $1.88B | $1.98B | $2.22B | $2.40B | $2.63B | — |
| Operating income | $478M | $791M | $836M | $867M | $1.10B | $1.14B |
| Net income | $244M | $107M | $378M | $615M | $782M | $805M |
| EPS (diluted) | $2.48 | $1.07 | $3.81 | $6.20 | $7.93 | — |
| Free cash flow | $397M | $395M | $613M | $778M | $972M | $926M |
| Gross margin | 44.6% | 43.7% | 43.2% | 44.0% | 44.2% | — |
| Operating margin | 11.3% | 17.4% | 16.3% | 15.9% | 18.6% | 18.9% |
| Net margin | 5.8% | 2.4% | 7.4% | 11.3% | 13.2% | 13.3% |
| Revenue growth | +35.9% | +7.4% | +13.3% | +6.2% | +8.7% | — |
| Cash + short-term investments | $348M | $208M | $207M | $172M | $440M | — |
| Total debt | $3.09B | $3.08B | $3.21B | $2.04B | $1.93B | — |
Fiscal years end Mar. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (STE)
P/E 28.1x · P/S 3.8x · EV/EBITDA 14.7x · EV/Sales 4.0x · P/FCF 24.5x · P/B 3.1x · FCF yield 4.09% · Earnings yield 3.56% · Dividend yield (paid, TTM) 1.09% · Buyback yield (TTM) 1.50% · Net debt $1.41B · EV $24.1B
P/E at fiscal year-ends: Mar 2026 27.9x, Mar 2025 36.5x, Mar 2024 59.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (STE)
1 of 80 tracked investors hold STE. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | <0.01% | $20K | Added +427.8% |
Analysts (STE)
Consensus Buy (mean 2.00 on a 1–5 scale), 8 analysts; mean target USD 259.17 (low 232, high 275).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | UBS | Target lowered | Buy | $275 → $270 |
| 2026-08-07 | Piper Sandler | Target raised | Overweight | $270 → $275 |
| 2026-07-28 | UBS | Initiated | Buy | $275 |
Total return (dividends reinvested) (STE)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -3.2% | +3.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -3.2% | +0.7% |
| Volatility (annualized) | 26.0% | 26.5% |
| Max drawdown | -25.4% (Jan 2026→Jun 2026) | -34.3% (Apr 2022→Oct 2022) |
Companies that name STE in their SEC reports
| Relationship to STE | Company | Filing | Sentence |
|---|---|---|---|
| customer | MiniMed Group, Inc. (MMED) | 10-K Jun 29, 2026 | “Our sole suppliers include Convatec Group plc for the infusion sets used in our insulin pumps, Forj Medical (f/k/a Intricon Corporation) for transmitters, and Steris plc and Steri-Tech Inc. for sterilization services.” |
STE analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.68 | $2.70 | -0.7% | $1.56B | 5 |
| Next quarter (ends Dec 2026) | $2.80 | $2.81 | -0.4% | $1.61B | 5 |
| Current fiscal year (ends Mar 2027) | $11.17 | $11.16 | +0.1% | $6.37B | 7 |
| Next fiscal year (ends Mar 2028) | $12.28 | $12.18 | +0.8% | $6.77B | 7 |
STE options: expected move
Options price a move of about ±7.1% (±$16.60) by Nov 20, 2026, which includes earnings on Nov 4, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 31.5% | ±7.1% |
| Dec 18, 2026 | 56 | 27.9% | ±8.7% |
| Mar 19, 2027 | 147 | 27.6% | ±13.9% |
| Jun 17, 2027 | 237 | 27.9% | ±17.8% |
30-day implied volatility 28.6% vs 22.5% realized over the last 30 trading days. Put/call ratio (volume) 0.11. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 232.22 |
|---|---|
| Change | ▲ 4.85% (up) |
| Previous Close | USD 221.48 |
| Open | USD 223 |
| Day Range | USD 222.78 – 232.32 |
| 52-Week Range | USD 195.14 – 269.44 |
| Volume | 1,024,626 shares |
| Market Cap | $22.64B |
| Exchange | NYQ |
Technical Analysis (STE)
Nexqual's technical model rates STE "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 66.27 (neutral) |
| vs SMA50 | Above (USD 220.34) |
| MACD | 2.71 (positive) |
Analyst Ratings (STE)
Wall Street analysts rate STE "Buy" based on 8 analysts, with a mean price target of USD 259.17 (range USD 232–275), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 259.17 |
| High Target | USD 275 |
| Low Target | USD 232 |
| Buy / Hold / Sell | 6 / 2 / 0 |
Earnings (STE)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 2.68 |
| Revenue Estimate | $1.56B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.59 vs est 2.49 ▲ beat |
| 2026-03-31 | USD 2.83 vs est 2.85 ▼ miss |
| 2025-12-31 | USD 2.53 vs est 2.53 ▼ miss |
| 2025-09-30 | USD 2.47 vs est 2.35 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (STE)
| Total Revenue | $6.04B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +7.30% |
| Gross Margin | +44.42% |
| Operating Margin | +19.15% |
| Profit Margin | +13.33% |
| ROE | +11.39% |
| Debt / Equity | 0.28 |
| Current Ratio | 1.91 |
| Total Cash | $482.30M |
| Total Debt | $2.04B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $925.60M (15.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (STE)
Nexqual rates STERIS plc's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 19% (last 12 months) |
| Balance Sheet | Strong — $482M cash and investments vs $1.89B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $926M (last 4 quarters to Jun 2026, SEC), 15% margin |
| Efficiency | Mixed — ROE 11%, ROA 6.8% |
Ownership (STE)
| Insider Ownership | +0.31% |
|---|---|
| Institutional Ownership | +100.91% |
| Shares Outstanding | 97.50M |
| Float | 97.08M |
| Short % of Float | +2.94% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (STE)
STERIS plc is led by Daniel A. Carestio, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:24 UTC.
| President, CEO & Director | Daniel A. Carestio |
|---|---|
| Senior VP, CFO & Chief Accounting Officer | Karen L. Burton |
| Senior VP & President of Healthcare | Cary L. Majors |
| Vice President of Investor Relations & Corporate Communications | Julie Winter |
Major Backers & Investors (STE)
Notable institutional backers of STERIS plc include Morgan Stanley, Massachusetts Financial Services Co., Wellington Management, according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 4.05% |
| Massachusetts Financial Services Co. | 3.9% |
| Wellington Management | 3.59% |
| Orbis Allan Gray Ltd | 2.75% |
| Generation Investment Management LLP | 2.34% |
| Fidelity | 1.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.7% |
| BlackRock | 9.05% |
| State Street | 5.2% |
| Geode Capital | 2.68% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHG | Koninklijke Philips N.V. NY Reg | USD 26.92 | ▲ 2.63% |
| ZBH | Zimmer Biomet Holdings, Inc. | USD 98.81 | ▲ 4.16% |
| DXCM | DexCom, Inc. | USD 78.32 | ▼ 2.42% |
| GEHC | GE HealthCare Technologies Inc. | USD 71.42 | ▲ 3.49% |
| PEN | Penumbra, Inc. | USD 324.96 | ▲ 0.43% |
| SNN | Smith & Nephew SNATS, Inc. | USD 30.88 | ▲ 5.64% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt